Intas’ Accord overcame Purdue in Hatch-Waxman litigation involving the originator’s controversial opioid, Oxycontin extended-release.

With Accord boasting a broad portfolio that encompasses generics, biosimilars, hybrid medicines and specialty products, Paul Tredwell – the firm’s executive vice-president for the Europe, Middle East and North Africa region – explains how this gives the company a unique position in the market.

A number of new drugs have taken a major step towards being approved for use in the EU after receiving the nod from the European Medicines Agency’s human medicines committee, the CHMP. Meanwhile, the marketing applications for three drugs have been withdrawn.

A swathe of generic lurasidone launches following the originator’s US patent expiry may trigger a shift in the antipsychotics space.